US protection ending in 2034: Nervous system
As of the edition of 20 October 2026, 27 drugs have US protection that ends in 2034 in nervous system; 15 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
27 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Belzutifan | Ends 2034 (patent) | Marketed | Merck & Co. | EPAS1 | 1 |
| Brincidofovir | Ends 2034 (patent) | Marketed | Emergent Biosolutions | 0 | |
| Cedazuridine | Ends 2034 (patent) | Marketed | Taiho | CDA | 1 |
| Daridorexant | Ends 2034 (patent) | Marketed | Idorsia Pharmaceuticals | HCRTR1, HCRTR2 | 4 |
| Daxibotulinumtoxina | Ends 2034 (computed from the first US licence) | Marketed | Crown | SNAP25 | 1 |
| Deferasirox | Ends 2034 (patent) | Marketed | Novartis | 0 | |
| Enasidenib | Ends 2034 (patent) | Marketed | Bristol Myers Squibb | IDH2 | 1 |
| Faricimab | Ends 2034 (computed from the first US licence) | Marketed | Roche | ANGPT2, VEGFA | 1 |
| Fezolinetant | Ends 2034 (patent) | Marketed | Astellas | TACR3 | 1 |
| Inclisiran sodium | Ends 2034 (patent) | Marketed | Novartis | PCSK9 | 0 |
| Ledipasvir | Ends 2034 (patent) | Marketed | Gilead Sciences | 0 | |
| Netarsudil | Ends 2034 (patent) | Marketed | Alcon | ROCK1, ROCK2 | 6 |
| Olipudase alfa | Ends 2034 (computed from the first US licence) | Marketed | Sanofi | 0 | |
| Palbociclib | Ends 2034 (patent) | Marketed | Pfizer | CDK4, CDK6 | 2 |
| Pegulicianine acetate | Ends 2034 (patent) | Marketed | Lumicell | 0 | |
| Relatlimab | Ends 2034 (computed from the first US licence) | Marketed | Bristol Myers Squibb | LAG3 | 1 |
| Remibrutinib | Ends 2034 (patent) | Marketed | Novartis | BTK | 1 |
| Rimegepant | Ends 2034 (patent) | Marketed | Pfizer | CALCRL | 0 |
| Riociguat | Ends 2034 (patent) | Marketed | Bayer | GUCY1A1, GUCY1A2, GUCY1B1 | 1 |
| Semaglutide | Ends 2034 (patent) | Marketed | Novo Nordisk | GLP1R | 0 |
| Sofosbuvir | Ends 2034 (patent) | Marketed | Gilead Sciences | 0 | |
| Tazemetostat | Ends 2034 (patent) | Marketed | Ipsen | EZH2 | 2 |
| Tucatinib | Ends 2034 (patent) | Marketed | Pfizer | ERBB2 | 0 |
| Ublituximab | Ends 2034 (computed from the first US licence) | Marketed | TG Therapeutics | MS4A1 | 2 |
| Vibegron | Ends 2034 (patent) | Marketed | Sumitomo Pharma | ADRB3 | 2 |
| Viltolarsen | Ends 2034 (patent) | Marketed | Nippon Shinyaku | DMD | 0 |
| Zavegepant | Ends 2034 (patent) | Marketed | Pfizer | CALCRL | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2034 in nervous system
In the product15 of these 27 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.